Singapore, Oct. 29 -- American multinational pharmaceutical company Merck (Known as Merck Sharp & Dohme or MSD outside the United States and Canada) has announced that the Health Sciences Authority (HSA) of Singapore has approved CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in adults 18 years of age and older.

CAPVAXIVE is a pneumococcal vaccine that helps protect adults against invasive pneumococcal disease and pneumococcal pneumonia caused by the indicated serotypes. In adults previously vaccinated with o...